Ezetimibe improves hepatic steatosis in relation to autophagy in obese and diabetic rats

World Journal of Gastroenterology

Volumn 21, Issue 25, 2015, Pages 7754-7763

  Chang, Eugene ^a   Kim, Lisa ^b   Park, Se Eun ^b   Rhee, Eun Jung ^b   Lee, Won Young ^b   Oh, Ki Won ^b   Park, Sung Woo ^b   Park, Cheol Young ^b,c  

^a Ewha Womans University   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c School of Medicine   (South Korea)

Author keywords

Autophagy; Ezetimibe; Hepatic steatosis; Nonalcoholic fatty liver disease

Indexed keywords

AUTOPHAGY PROTEIN 5; AUTOPHAGY PROTEIN 7; BECLIN 1; CELL PROTEIN; EZETIMIBE; FATTY ACID; GLUCOSE; INSULIN; MESSENGER RNA; MICROTUBULE ASSOCIATED PROTEIN; MICROTUBULE ASSOCIATED PROTEIN LIGHT CHAIN 3; PALMITIC ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BAFILOMYCIN A1; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; HYPOCHOLESTEROLEMIC AGENT; LIPID; MACROLIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; CONTROLLED STUDY; DRUG EFFECT; FATTY LIVER; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; LIPID STORAGE; LIVER CELL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PROTEIN EXPRESSION; RAT; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; BLOOD; CELL CULTURE; COMPLICATION; DIABETES MELLITUS, TYPE 2; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LIVER; METABOLISM; PATHOLOGY; ULTRASTRUCTURE;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AUTOPHAGY; BIOMARKERS; BLOOD GLUCOSE; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; EZETIMIBE; FATTY LIVER; GENE EXPRESSION REGULATION; HEPATOCYTES; LIPIDS; LIVER; MACROLIDES; MALE; OBESITY; PALMITIC ACID; RATS, INBRED OLETF; RNA, MESSENGER;

EID: 84936806623     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i25.7754     Document Type: Article

References (50)

1. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006;40 Suppl 1:S5-10 [PMID: 16540768 DOI: 10.1097/01.mcg.0000168638.84840.ff]
2. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008;28:339-350 [PMID: 18956290 DOI: 10.1055/s-0028-1091978]
3. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-1395 [PMID: 15565570 DOI: 10.1002/hep. 20466]
4. Byrne CD. Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management. Diabet Med 2012;29:1098-1107 [PMID: 22672330 DOI: 10.1111/j.1464-5491.2012.03732.x]
5. Altmann SW, Davis HR, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, Graziano MP. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004;303:1201-1204 [PMID: 14976318 DOI: 10.1126/science.1093131]
6. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, Crona JH, Davis HR, Dean DC, Detmers PA, Graziano MP, Hughes M, Macintyre DE, Ogawa A, O'neill KA, Iyer SP, Shevell DE, Smith MM, Tang YS, Makarewicz AM, Ujjainwalla F, Altmann SW, Chapman KT, Thornberry NA. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci USA 2005;102:8132-8137 [PMID: 15928087 DOI: 10.1073/pnas.0500269102]
7. Deushi M, Nomura M, Kawakami A, Haraguchi M, Ito M, Okazaki M, Ishii H, Yoshida M. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett 2007;581:5664-5670 [PMID: 18022391 DOI: 10.1016/j.febslet.2007.11.023]
8. Nomura M, Ishii H, Kawakami A, Yoshida M. Inhibition of hepatic Niemann-Pick C1-like 1 improves hepatic insulin resistance. Am J Physiol Endocrinol Metab 2009;297:E1030-E1038 [PMID: 19654286 DOI: 10.1152/ajpendo.00343.2009]
9. Takase H, Dohi Y, Okado T, Hashimoto T, Goto Y, Kimura G. Effects of ezetimibe on visceral fat in the metabolic syndrome: a randomised controlled study. Eur J Clin Invest 2012;42:1287-1294 [PMID: 23033884 DOI: 10.1111/eci.12000]
10. Davis HR, Compton DS, Hoos L, Tetzloff G. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler Thromb Vasc Biol 2001;21:2032-2038 [PMID: 11742881 DOI: 10.1161/hq1201.100260]
11. Mangili OC, Moron Gagliardi AC, Mangili LC, Mesquita CH, Machado Cesar LA, Tanaka A, Schaefer EJ, Maranhão RC, Santos RD. Favorable effects of ezetimibe alone or in association with simvastatin on the removal from plasma of chylomicrons in coronary heart disease subjects. Atherosclerosis 2014;233:319-325 [PMID: 24503114 DOI: 10.1016/j.atherosclerosis.2013.12.008]
12. Davies JP, Scott C, Oishi K, Liapis A, Ioannou YA. Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J Biol Chem 2005;280:12710-12720 [PMID: 15671032 DOI: 10.1074/jbc. M409110200]
13. Chan DC, Watts GF, Gan SK, Ooi EM, Barrett PH. Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care 2010;33:1134-1139 [PMID: 20185740 DOI: 10.2337/dc09-1765]
14. Park H, Shima T, Yamaguchi K, Mitsuyoshi H, Minami M, Yasui K, Itoh Y, Yoshikawa T, Fukui M, Hasegawa G, Nakamura N, Ohta M, Obayashi H, Okanoue T. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 2011;46:101-107 [PMID: 20658156 DOI: 10.1007/s00535-010-0291-8]
15. Yoneda M, Fujita K, Nozaki Y, Endo H, Takahashi H, Hosono K, Suzuki K, Mawatari H, Kirikoshi H, Inamori M, Saito S, Iwasaki T, Terauchi Y, Kubota K, Maeyama S, Nakajima A. Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study. Hepatol Res 2010;40:566-573 [PMID: 20412324 DOI: 10.1111/j.1872-034X.2010.00644.x]
16. Zheng S, Hoos L, Cook J, Tetzloff G, Davis H, Van Heek M, Hwa JJ. Ezetimibe improves high fat and cholesterol diet-induced nonalcoholic fatty liver disease in mice. Eur J Pharmacol 2008;584:118-124 [PMID: 18329014 DOI: 10.1016/j.ejphar.2008.01.045]
17. Muraoka T, Aoki K, Iwasaki T, Shinoda K, Nakamura A, Aburatani H, Mori S, Tokuyama K, Kubota N, Kadowaki T, Terauchi Y. Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet. Metabolism 2011;60:617-628 [PMID: 20673929 DOI: 10.1016/j.metabol.2010.06.008]
18. Matono T, Koda M, Tokunaga S, Kato J, Sugihara T, Ueki M, Murawaki Y. Therapeutic effects of ezetimibe for non-alcoholic steatohepatitis in fatty liver shionogi-ob/ob mice. Hepatol Res 2011;41:1240-1248 [PMID: 21951423 DOI: 10.1111/j.1872-034X.2011.00888.x]
19. Wang X, Sugimoto K, Fujisawa T, Shindo N, Minato S, Kamada Y, Hamano M, Ohishi M, Ikegami H, Rakugi H. Novel effect of ezetimibe to inhibit the development of non-alcoholic fatty liver disease in Fatty Liver Shionogi mouse. Hepatol Res 2014;44:102-113 [PMID: 23510093 DOI: 10.1111/hepr.12092]
20. Fukuda M, Nakamura T, Kataoka K, Nako H, Tokutomi Y, Dong YF, Yasuda O, Ogawa H, Kim-Mitsuyama S. Ezetimibe ameliorates cardiovascular complications and hepatic steatosis in obese and type 2 diabetic db/db mice. J Pharmacol Exp Ther 2010;335:70-75 [PMID: 20651026 DOI: 10.1124/jpet.110.170373]
21. Jia L, Ma Y, Rong S, Betters JL, Xie P, Chung S, Wang N, Tang W, Yu L. Niemann-Pick C1-Like 1 deletion in mice prevents high-fat diet-induced fatty liver by reducing lipogenesis. J Lipid Res 2010;51:3135-3144 [PMID: 20699423 DOI: 10.1194/jlr. M006353]
22. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature 2008;451:1069-1075 [PMID: 18305538 DOI: 10.1038/nature06639]
23. Mizushima N, Yamamoto A, Matsui M, Yoshimori T, Ohsumi Y. In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Mol Biol Cell 2004;15:1101-1111 [PMID: 14699058 DOI: 10.1091/mbc. E03-09-0704]
24. Ogata M, Hino S, Saito A, Morikawa K, Kondo S, Kanemoto S, Murakami T, Taniguchi M, Tanii I, Yoshinaga K, Shiosaka S, Hammarback JA, Urano F, Imaizumi K. Autophagy is activated for cell survival after endoplasmic reticulum stress. Mol Cell Biol 2006;26:9220-9231 [PMID: 17030611 DOI: 10.1128/mcb.01453-06]
25. Ding WX, Ni HM, Gao W, Yoshimori T, Stolz DB, Ron D, Yin XM. Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability. Am J Pathol 2007;171:513-524 [PMID: 17620365 DOI: 10.2353/ajpath.2007.070188]
26. Tallóczy Z, Jiang W, Virgin HW, Leib DA, Scheuner D, Kaufman RJ, Eskelinen EL, Levine B. Regulation of starvation- and virus-induced autophagy by the eIF2alpha kinase signaling pathway. Proc Natl Acad Sci USA 2002;99:190-195 [PMID: 11756670 DOI: 10.1073/pnas.012485299]
27. Singh R, Kaushik S, Wang Y, Xiang Y, Novak I, Komatsu M, Tanaka K, Cuervo AM, Czaja MJ. Autophagy regulates lipid metabolism. Nature 2009;458:1131-1135 [PMID: 19339967 DOI: 10.1038/nature07976]
28. Koga H, Kaushik S, Cuervo AM. Altered lipid content inhibits autophagic vesicular fusion. FASEB J 2010;24:3052-3065 [PMID: 20375270 DOI: 10.1096/fj.09-144519]
29. Mei S, Ni HM, Manley S, Bockus A, Kassel KM, Luyendyk JP, Copple BL, Ding WX. Differential roles of unsaturated and saturated fatty acids on autophagy and apoptosis in hepatocytes. J Pharmacol Exp Ther 2011;339:487-498 [PMID: 21856859 DOI: 10.1124/jpet.111.184341]
30. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 1992;41:1422-1428 [PMID: 1397718 DOI: 10.2337/diab.41.11.1422]
31. Kawano K, Hirashima T, Mori S, Natori T. OLETF (Otsuka Long-Evans Tokushima Fatty) rat: a new NIDDM rat strain. Diabetes Res Clin Pract 1994;24 Suppl: S317-S320 [PMID: 7859627 DOI: 10.1016/0168-8227 (94) 90269-0]
32. Song Z, Song M, Lee D Y, Liu Y, Deaciuc I V, McClain CJ. Silymarin prevents palmitate-induced lipotoxicity in HepG2 cells: involvement of maintenance of Akt kinase activation. Basic Clin Pharmacol Toxicol 2007;101:262-268 [PMID: 17845508 DOI: 10.1111/j.1742-7843.2007.00116.x]
33. Yang SJ, Choi JM, Chae SW, Kim WJ, Park SE, Rhee EJ, Lee WY, Oh KW, Park SW, Kim SW, Park CY. Activation of peroxisome proliferator-activated receptor gamma by rosiglitazone increases sirt6 expression and ameliorates hepatic steatosis in rats. PLoS One 2011;6:e17057 [PMID: 21373642 DOI: 10.1371/journal.pone.0017057]
34. Klionsky DJ, Cregg JM, Dunn WA, Emr SD, Sakai Y, Sandoval IV, Sibirny A, Subramani S, Thumm M, Veenhuis M, Ohsumi Y. A unified nomenclature for yeast autophagy-related genes. Dev Cell 2003;5:539-545 [PMID: 14536056 DOI: 10.1016/S1534-5807 (03) 00296-X]
35. Mizushima N, Yamamoto A, Hatano M, Kobayashi Y, Kabeya Y, Suzuki K, Tokuhisa T, Ohsumi Y, Yoshimori T. Dissection of autophagosome formation using Apg5-deficient mouse embryonic stem cells. J Cell Biol 2001;152:657-668 [PMID: 11266458 DOI: 10.1083/jcb.152.4.657]
36. Kametaka S, Okano T, Ohsumi M, Ohsumi Y. Apg14p and Apg6/Vps30p form a protein complex essential for autophagy in the yeast, Saccharomyces cerevisiae. J Biol Chem 1998;273:22284-22291 [PMID: 9712845 DOI: 10.1074/jbc.273.35.22284]
37. Ohsumi Y, Mizushima N. Two ubiquitin-like conjugation systems essential for autophagy. Semin Cell Dev Biol 2004;15:231-236 [PMID: 15209383 DOI: 10.1016/j.semcdb.2003.12.004]
38. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y, Yoshimori T. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 2000;19:5720-5728 [PMID: 11060023 DOI: 10.1093/emboj/19.21.5720]
39. Mizushima N, Yoshimori T. How to interpret LC3 immunoblotting. Autophagy 2007;3:542-545 [PMID: 17611390 DOI: 10.4161/auto.4600]
40. Ichimura Y, Komatsu M. Selective degradation of p62 by autophagy. Semin Immunopathol 2010;32:431-436 [PMID: 20814791 DOI: 10.1007/s00281-010-0220-1]
41. Yang SJ, Choi JM, Kim L, Kim BJ, Sohn JH, Kim WJ, Park SE, Rhee EJ, Lee WY, Oh KW, Park SW, Kim SW, Park CY. Chronic administration of ezetimibe increases active glucagon-like peptide-1 and improves glycemic control and pancreatic beta cell mass in a rat model of type 2 diabetes. Biochem Biophys Res Commun 2011;407:153-157 [PMID: 21371430 DOI: 10.1016/j.bbrc.2011.02.129]
42. Park SW. Intestinal and hepatic niemann-pick c1-like 1. Diabetes Metab J 2013;37:240-248 [PMID: 23991401 DOI: 10.4093/dmj.2013.37.4.240]
43. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998;114:842-845 [PMID: 9547102 DOI: 10.1016/S0016-5085 (98) 70599-2]
44. Liu K, Czaja MJ. Regulation of lipid stores and metabolism by lipophagy. Cell Death Differ 2013;20:3-11 [PMID: 22595754 DOI: 10.1038/cdd.2012.63]
45. Wang Y, Singh R, Xiang Y, Czaja MJ. Macroautophagy and chaperone-mediated autophagy are required for hepatocyte resistance to oxidant stress. Hepatology 2010;52:266-277 [PMID: 20578144 DOI: 10.1002/hep. 23645]
46. Yang L, Li P, Fu S, Calay ES, Hotamisligil GS. Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance. Cell Metab 2010;11:467-478 [PMID: 20519119 DOI: 10.1016/j.cmet.2010.04.005]
47. Komatsu M, Waguri S, Ueno T, Iwata J, Murata S, Tanida I, Ezaki J, Mizushima N, Ohsumi Y, Uchiyama Y, Kominami E, Tanaka K, Chiba T. Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. J Cell Biol 2005;169:425-434 [PMID: 15866887 DOI: 10.1083/jcb.200412022]
48. Mathew R, Karp CM, Beaudoin B, Vuong N, Chen G, Chen HY, Bray K, Reddy A, Bhanot G, Gelinas C, Dipaola RS, Karantza-Wadsworth V, White E. Autophagy suppresses tumorigenesis through elimination of p62. Cell 2009;137:1062-1075 [PMID: 19524509 DOI: 10.1016/j.cell.2009.03.048]
49. Pyo JO, Jang MH, Kwon YK, Lee HJ, Jun. JI, Woo HN, Cho DH, Choi B, Lee H, Kim JH, Mizushima N, Oshumi Y, Jung YK. Essential roles of Atg5 and FADD in autophagic cell death: dissection of autophagic cell death into vacuole formation and cell death. J Biol Chem 2005;280:20722-20729 [PMID: 15778222 DOI: 10.1074/jbc. M413934200]
50. Yamamura T, Ohsaki Y, Suzuki M, Shinohara Y, Tatematsu T, Cheng J, Okada M, Ohmiya N, Hirooka Y, Goto H, Fujimoto T. Inhibition of Niemann-Pick-type C1-like1 by ezetimibe activates autophagy in human hepatocytes and reduces mutant α1-antitrypsin Z deposition. Hepatology 2014;59:1591-1599 [PMID: 24214142 DOI: 10.1002/hep. 26930]